BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7891341)

  • 1. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats.
    Sato M; Kim J; Short LL; Slemenda CW; Bryant HU
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1252-9. PubMed ID: 7891341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats.
    Sato M; McClintock C; Kim J; Turner CH; Bryant HU; Magee D; Slemenda CW
    J Bone Miner Res; 1994 May; 9(5):715-24. PubMed ID: 8053401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
    Armamento-Villareal R; Sheikh S; Nawaz A; Napoli N; Mueller C; Halstead LR; Brodt MD; Silva MJ; Galbiati E; Caruso PL; Civelli M; Civitelli R
    J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
    Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR
    J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.
    Sato M; Bryant HU; Iversen P; Helterbrand J; Smietana F; Bemis K; Higgs R; Turner CH; Owan I; Takano Y; Burr DB
    J Pharmacol Exp Ther; 1996 Oct; 279(1):298-305. PubMed ID: 8859007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
    Evans G; Bryant HU; Magee D; Sato M; Turner RT
    Endocrinology; 1994 May; 134(5):2283-8. PubMed ID: 8156931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
    Uyar Y; Baytur Y; Inceboz U; Demir BC; Gumuser G; Ozbilgin K
    Maturitas; 2009 Jul; 63(3):261-7. PubMed ID: 19386450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
    Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
    J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raloxifene preserves bone strength and bone mass in ovariectomized rats.
    Turner CH; Sato M; Bryant HU
    Endocrinology; 1994 Nov; 135(5):2001-5. PubMed ID: 7956922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile.
    Gallo D; Zannoni GF; Apollonio P; Martinelli E; Ferlini C; Passetti G; Riva A; Morazzoni P; Bombardelli E; Scambia G
    Menopause; 2005; 12(5):589-600. PubMed ID: 16145313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.
    Sato M; Turner CH; Wang T; Adrian MD; Rowley E; Bryant HU
    J Pharmacol Exp Ther; 1998 Oct; 287(1):1-7. PubMed ID: 9765314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the antiestrogenic environmental pollutant 3,3',4,4', 5-pentachlorobiphenyl (PCB #126) in rat bone and uterus: diverging effects in ovariectomized and intact animals.
    Lind PM; Eriksen EF; Sahlin L; Edlund M; Orberg J
    Toxicol Appl Pharmacol; 1999 Feb; 154(3):236-44. PubMed ID: 9931283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tanshinone prevents cancellous bone loss induced by ovariectomy in rats.
    Cui L; Wu T; Liu YY; Deng YF; Ai CM; Chen HQ
    Acta Pharmacol Sin; 2004 May; 25(5):678-84. PubMed ID: 15132837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator.
    Kauffman RF; Bensch WR; Roudebush RE; Cole HW; Bean JS; Phillips DL; Monroe A; Cullinan GJ; Glasebrook AL; Bryant HU
    J Pharmacol Exp Ther; 1997 Jan; 280(1):146-53. PubMed ID: 8996192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential mRNA expression profiles in proximal tibia of aged rats in response to ovariectomy and low-Ca diet.
    Zhang Y; Dong XL; Leung PC; Wong MS
    Bone; 2009 Jan; 44(1):46-52. PubMed ID: 18848653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LY353381 x HCl: an improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1-34).
    Sato M; Zeng GQ; Rowley E; Turner CH
    Endocrinology; 1998 Nov; 139(11):4642-51. PubMed ID: 9794476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen supplementation modulates effects of the endocrine disrupting pollutant PCB126 in rat bone and uterus: diverging effects in ovariectomized and intact animals.
    Lind PM; Eriksen EF; Lind L; Orberg J; Sahlin L
    Toxicology; 2004 Jul; 199(2-3):129-36. PubMed ID: 15147787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raloxifene and vitamin K2 combine to improve the femoral neck strength of ovariectomized rats.
    Iwamoto J; Yeh JK; Schmidt A; Rowley E; Stanfield L; Takeda T; Sato M
    Calcif Tissue Int; 2005 Aug; 77(2):119-26. PubMed ID: 16059775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system.
    Sliwiński L; Folwarczna J; Nowińska B; Cegieła U; Pytlik M; Kaczmarczyk-Sedlak I; Trzeciak H; Trzeciak HI
    Acta Biochim Pol; 2009; 56(2):261-70. PubMed ID: 19401787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of 17beta-estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency.
    Naves-Díaz M; Carrillo-López N; Rodríguez-Rodríguez A; Braga S; Fernández-Coto T; Lopez-Novoa JM; López-Hernández F; Cannata-Andía JB
    Menopause; 2010 Jul; 17(4):766-71. PubMed ID: 20386345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.